Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study.
Saved in:
| Title: | Bortezomib in combination with fludarabine plus cyclophosphamide for patients with relapsed or refractory mantle-cell lymphoma: results of the LYM-4003 study. |
|---|---|
| Authors: | Wang XX; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Gao Y; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Jin J; Department of Hematology, The First Affiliated Hospital, Zhejiang University, Hangzhou, China., Cao JN; Department of Medical Oncology, Fudan University Cancer Center, Shanghai, China., Feng JF; Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, China., Wang HQ; Department of Medical Oncology, People's Hospital of Tianjin, Tianjin, China., Zhang HL; Department of Medical Oncology, Tianjin Cancer Hospital, Tianjin, China., Cai QQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Li ZM; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Jiang WQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China., Huang HQ; State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China. huanghq_sysucc@163.com.; Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, 510060, Guangdong, China. huanghq_sysucc@163.com. |
| Corporate Authors: | Lymphoma Committee, Chinese Anti-Cancer Association (CACA) |
| Source: | Annals of hematology [Ann Hematol] 2021 Dec; Vol. 100 (12), pp. 2961-2968. Date of Electronic Publication: 2021 Jul 31. |
| Publication Type: | Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0584 |
|---|---|
| DOI: | 10.1007/s00277-021-04619-4 |
